The safety and tolerability of atypical antipsychotics in bipolar disorder

Bibliography

• GOLDSTEIN JM: The new generation of antipsychotic drugs: how atypical are they? Int. J. Neuropsychophannacol (2000) 3:339–349.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review onwhat makes an aAP atypical.
   Google Scholar
• SPRAGUE DA, LOEWEN PS, RAYMOND CB: Selection of atypical antipsychotics for the management of schizophrenia. Ann. Phannacother. (2004) 38:313–319.
   PubMed Web of Science ®Google Scholar
• SUSSMAN N: Choosing an atypical antipsychotic. Int. Clin. Psychophannacol (2002) 17\(Suppl. 3):S29–S33.
   Google Scholar
• WEISSMAN MM, BLAND RC, CANINO GJ et al.: Cross-national epidemiology of major depression and bipolar disorder. JAMA (1996) 276:293–299.
   PubMed Web of Science ®Google Scholar
• ANGST J, GAMMA A: A new bipolar spectrum concept: a brief review. Bipolar disord. (2002) 4\(Suppl. 1):11–14.
   Google Scholar
• TOHEN M, VIETA E, CALABRESE J et al: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry (2003) 60:1079–1088.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of olanzapine in bipolar disorder.
   Google Scholar
• CALABRESE JR: Double-blind, placebo-controlled study of quetiapine in bipolar depression. Proceedings of the 157th APA Conference (2004) NR 756.
   Google Scholar
• SMULEVICH AB, KHANNA S, EERDEKENS M et al.: Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur. Neuropsychophannacol (2005) 15:75–84.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of risperidone in bipolar disorder.
   Google Scholar
• BOWDEN CL, GRUNZE H, MULLEN J et al.: A Randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry (2005) 66:111–121.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of quetiapine in bipolar disorder.
   Google Scholar
• LYSENG-WILLIAMSON KA, PERRY CM: Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs (2004) 18:367–376.
   PubMed Web of Science ®Google Scholar
• TOHEN M, SANGER TM, MCELROY SL et al: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Arm J. Psychiatry (1999) 156:702–709.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of this olanzapine in bipolar disorder.
   Google Scholar
• TOHEN M, JACOBS TG, GRUNDY SL et al: Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. Arch. Gen. Psychiatry (2000) 57:841–849.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of olanzapine in bipolar disorder.
   Google Scholar
• HIRSCHFELD RIVI, KECK PE, JR., KRAMER M et al: Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Arm Psychiatry (2004) 161:1057–1065.
   Google Scholar
• •A pivotal, published study for the efficacy of risperidone in bipolar disorder.
   Google Scholar
• KHANNA S, VIETA E, LYONS B et al: Risperidone in the treatment of acute bipolar mania: a double-blind, placebo-controlled study of 290 patients. Eur. Neuropsychophannacol (2003) 13\(Suppl. 4):314–315.
   Google Scholar
• TOHEN M, MARNEROS A, GREIL W et al.: Olanzapine versus lithium in Relapse/ recurrence prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Arm J. Psychiatry (2005) in press.
   Google Scholar
• •A pivotal, published study for the efficacy of olanzapine in bipolar disorder.
   Google Scholar
• TOHEN M, KETTER TA, ZARATE CA et al.: Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Arm J. Psychiatry (2003) 160:1263–1271.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of olanzapine in bipolar disorder.
   Google Scholar
• TOHEN M, BOWDEN C, CALABRESE J et al.: Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial. World J. Biol. Psychiatry (2004) 5\(Suppl. 1):51.
   Google Scholar
• TOHEN M, CHENGAPPA KN, SUPPES T et al: Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br. J Psychiatry (2004) 184:337–345.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of this antipsychotic in bipolar disorder.
   Google Scholar
• KECK PE, JR., VERSIANI M, POTKIN S et al.: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Ain. J. Psychiatry (2003) 160:741–748.
   Google Scholar
• •A pivotal, published study for the efficacy of ziprasidone in bipolar disorder.
   Google Scholar
• KECK PE, MARCUS R, TOURKODIMITRIS S et al: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Ain. J. Psychiatry (2003) 160:1651–1658.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of aripiprazole in bipolar disorder.
   Google Scholar
• GRUNZE H, KASPER S, GOODWIN G et al.: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders. Part II: treatment of mania. World J. Biol. Psychiatry (2003) 4:5–13.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive overview on treatmentoption in bipolar mania.
   Google Scholar
• GRUNZE H, KASPER S, GOODWIN G et al.: The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders. Part III: Maintenance treatment. World J. Biol. Psychiatry (2004) 5:120–135.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive overview on treatmentoptions for maintenance.
   Google Scholar
• MCCORMACK PL, WISEMAN LR: Olanzapine: a review of its use in the management of bipolar I disorder. Drugs (2004) 64:2709–2726.
   PubMed Web of Science ®Google Scholar
• KANE JM: The role of neuroleptics in manic-depressive illness. J. Clin. Psychiatry (1988) 49(Suppl.):12–14.
   Google Scholar
• KANE JM: Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J. Clin. Psychiatry (2004) 65\(Suppl. 9):16–20.
   Google Scholar
• TOHEN M, GOLDBERG JF, GONZALEZ-PINTO ARRILLAGA AM et al.: A 12-week, double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry (2003) 60:1218–1226.
   Google Scholar
• •A pivotal, published study for the efficacy of olanzapine in bipolar disorder.
   Google Scholar
• TOHEN M, JACOBS TG, TOMA V et al: Olanzapine in the treatment of mania: a placebo-controlled four-week study. Eur. Neuropsychophannacol (1999) 9\(Suppl. 5):247.
   Google Scholar
• RACHID F, BERTSCHY G, BONDOLFI G et al.: Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J. Clin. Psychiatry (2004) 65:1537–1545.
   PubMed Web of Science ®Google Scholar
• TOHEN M, BAKER RW, ALTSHULER LL et al: Olanzapine versus divalproex in the treatment of acute mania. Am. .1 Psychiatry (2002) 159:1011–1017.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of olanzapine in bipolar disorder.
   Google Scholar
• BAKER RW, ZARATE C, BROWN E et al.: A three-week comparison of olanzapine versus risperidone in the treatment of bipolar mania: Improvement in manic and depressive symptoms and treatment adherence. 156th Annual meeting APA abstracts (2003).
   Google Scholar
• ZAJECKA JM, WEISLER R, SACHS Get al.: A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry (2002) 63:1148–1155.
   Google Scholar
• •A pivotal, published study for the efficacy of olanzapine in bipolar disorder.
   Google Scholar
• BERK M, ICHIM L, BROOKS: Olanzapine compared to lithium in mania: A double-blind randomized controlled trial. Lit. Clin. Psychopharmacol (1999) 14:339–343.
   PubMed Web of Science ®Google Scholar
• YATHAM LN, PAULSSON B, MULLEN J et al.: Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. I Clin. Psychopharmacol (2004) 24:599–606.
   Google Scholar
• •A pivotal, published study for the efficacy of quetiapine in bipolar disorder.
   Google Scholar
• SACHS G, CHENGAPPA KN, SUPPES T et al: Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. (2004) 6:213–223.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of quetiapine in bipolar disorder.
   Google Scholar
• MCINTYRE RS, BRECHER M, PAULSSON B: Quetiapine as monotherapy for bipolar mania: A double blind randomized parallel group placebo controlled trial. Eur. Neuropsychopharmacol (2005) in press.
   Google Scholar
• •A pivotal, published study for the efficacy of quetiapine in bipolar disorder.
   Google Scholar
• SEGAL J, BERK M, BROOK S: Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin. Neuropharmacol (1998) 21:176–180.
   PubMed Web of Science ®Google Scholar
• SACHS GS, GROSSMAN F, GHAEMI SN et al: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry (2002) 159:1146–1154.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of risperidone in bipolar disorder.
   Google Scholar
• YATHAM LN, GROSSMAN F, AUGUSTYNS I et al: Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. BE J. Psychiatry (2003) 182:141–147.
   PubMed Web of Science ®Google Scholar
• •A pivotal, published study for the efficacy of risperidone in bipolar disorder.
   Google Scholar
• SACHS G, SANCHEZ R, MARCUS R et al: Aripiprazole versus placebo in patients with an acute manic or mixed episode. Proc. APA Annual Meeting (2004) NR 742.
   Google Scholar
• MARCUS R, CARSON W, MCQUADE R et al.: Overview of safety and tolerability of aripiprazole in acute mania. Proc. APA Annual Meeting (2004) NR 796.
   Google Scholar
• POTKIN S, SPRAGUE R, KECK PE et al: Ziprasidone in bipolar mania: efficacy across patient subgroups. Proc. APA Annual Meeting (2004) NR 777.
   Google Scholar
• KECK PE, POTKIN S, GILLER E et al: Ziprasidone's long-term efficacy and safety in bipolar disorder. Proc. APA Annual Meeting (2004) NR 745.
   Google Scholar
• KECK PE, JR., SANCHEZ R, MARCUS R et al.: Aripiprazole for relapse prevention in bipolar Disorder in a 26-week trial. Proc. APA Annual Meeting (2004) NR 796.
   Google Scholar
• NASRALLAH HA, LOEBEL AD, MURRAY SR et al.: Lipid profile pre- and post-treatment in ziprasidone clinical trials. Proc. APA Annual Meeting (2004) NR 387.
   Google Scholar
• FLEISCHHACKER WW, OEHL MA, HUMMER M: Factors influencing compliance in schizophrenia patients. Clin. Psychiatry (2003) 64 (Suppl. 1 6) :10-13.
   Google Scholar
• ANGST F, STASSEN HH, CLAYTON PJ et al.: Mortality of patients with mood disorders: follow-up over 34-38 years. J. Affect. Disord. (2002) 68:167–181.
   PubMed Web of Science ®Google Scholar
• WYATT RJ, HENTER ID, MOJTABAI R et al.: Height, weight and body mass index (BMI) in psychiatrically ill US Armed Forces personnel. Psycho]. Med. (2003) 33:363–368.
   PubMed Web of Science ®Google Scholar
• MCELROY SL, FRYE MA, SUPPES T et al: Correlates of overweight and obesity in 644 patients with bipolar disorder. Psychiatry(2002) 63:207–213.
   Google Scholar
• •One of the best naturalistic studies illustrating the problem of overweight in bipolar patients.
   Google Scholar
• FAGIOLINI A, FRANK E, HOUCK PR et al: Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J. Clin. Psychiatry (2002) 63:528–533.
   PubMed Web of Science ®Google Scholar
• FAGIOLINI A, KUPFER DJ, HOUCK PR et al: Obesity as a correlate ofoutcome in patients with bipolar I disorder. Am. J. Psychiatry (2003) 160:112–117.
   PubMed Web of Science ®Google Scholar
• HASLER G, PINE DS, GAMMA A et al: The associations between psychopathology and being overweight: a 20-year prospective study. Psycho]. Med. (2004) 34:1047–1057.
   PubMed Web of Science ®Google Scholar
• MELKERSSON KI, HULTING AL, BRISMAR KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. I Clin. Psychiatry (2000) 61:742–749.
   PubMed Web of Science ®Google Scholar
• WIRSHING DA: Adverse effects of atypical antipsychotics. I Clin. Psychiatry (2001) 62\(Suppl. 21):7–10.
   Google Scholar
• BAUMAN AE: Updating the evidence that physical activity is good for health: an epidemiological review 2000-2003. Sci. Med. Sport (2004) 7:6–19.
   Google Scholar
• BLUMENTHAL JA, BABYAK MA, MOORE KA et al.: Effects of exercise training on older patients with major depression. Arch. Intern. Med. (1999) 159:2349–2356.
   PubMed Web of Science ®Google Scholar
• KANE JM, BARRETT EJ, CASEY DE et al.: Metabolic effects of treatment with atypical antipsychotics. I Clin. Psychiatry (2004) 65:1447–1455.
   PubMed Web of Science ®Google Scholar
• •A comprehensive state-of-knowledge review.
   Google Scholar
• BERGMAN RN, ADER M: Atypical antipsychotics and glucose homeostasis. Clin. Psychiatry (2005) 66:504–514.
   PubMed Web of Science ®Google Scholar
• •A comprehensive state-of-knowledge review.
   Google Scholar
• POIRIER P, LEMIEUX I, MAURIEGE P et al: Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension (2005) 45:363–367.
   PubMed Web of Science ®Google Scholar
• POIRIER P, DESPRES JP: Waist circumference, visceral obesity, and cardiovascular risk. J. Cardiopulm. Rehabil (2003) 23:161–169.
   PubMedGoogle Scholar
• MCINTYRE RS, KONARSKI JZ: Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. I Clin. Psychiatry (2005) 66\(Suppl. 3):28–36.
   Google Scholar
• •A comprehensive state-of-knowledge review.
   Google Scholar
• ADER M, KIM SP, CATALANO KJ et al:Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes (2005) 54:862–871.
   PubMed Web of Science ®Google Scholar
• SOWELL M, MUKHOPADHYAY N, CAVAZZONI P et al: Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. I OM Endocrinol Metab. (2003) 88:5875–5880.
   PubMed Web of Science ®Google Scholar
• SOWELL MO, MUKHOPADHYAY N, CAVAZZONI P et al: Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. ./. Clin. Endocrinol Metab. (2002) 87:2918–2923.
   PubMed Web of Science ®Google Scholar
• ANANTH J, PARAMESWARAN S, GUNATILAKE S: Side effects of atypical antipsychotic drugs. Curr. Pharm. Des. (2004) 10:2219–2229.
   PubMed Web of Science ®Google Scholar
• COHEN D: Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry (2004) 37:1–11.
   PubMed Web of Science ®Google Scholar
• •A comprehensive state-of-knowledge review.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION: Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry (2004) 65:267–272.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive state-of-knowledgereview.
   Google Scholar
• MITHAT B, ALPASLAN T, BULENT C et al.: Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus Type 1 in a patient treated with valproate and lithium - a case report. Pharmacopsychiatry (2005) 38:105–106.
   PubMed Web of Science ®Google Scholar
• KILBOURNE AM, CORNELIUS JR, HAN X et al: Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. (2004) 6:368–373.
   PubMed Web of Science ®Google Scholar
• CASEY DE: Dyslipidemia and atypical antipsychotic drugs. J. Clin. Psychiatry (2004) 65\(Suppl. 18):27–35.
   Google Scholar
• Seroquel (quetiapine fumarate) tablets (pachage insert). Wilmington, Del: AstraZeneca Pharmaceuticals LP (2003) 1–27.
   Google Scholar
• ANNIS AM, CAULDER MS, COOK ML et al: Family history, diabetes, and other demographic and risk factors among participants of the National Health and Nutrition Examination Survey 1999-2002. Prey. Chronic. Dis. (2005) 2:A19.
   PubMedGoogle Scholar
• NASRALLAH HA, CHURCHILL CM, HAMDAN-ALLAN GA: Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am. I Psychiatry (1988) 145:1455–1456.
   PubMed Web of Science ®Google Scholar
• FLEISCHHACKER WW, BARNAS C, GUNTHER V et al.: Mood-altering effects of biperiden in healthy volunteers. J. Affect. Disord. (1987) 12:153–157.
   PubMed Web of Science ®Google Scholar
• ROSENQUIST KJ, GHAEMI NS, HSU DJ et al: EPS With Atypical Neuroleptics in Bipolar Disorder. Proc. APA Annual Meeting (2004) NR 153.
   Google Scholar
• CASTILLO J, MUNOZ P, GUITERA V et al: Epidemiology of chronic daily headache in the general population. Headache (1999) 39:190–196.
   PubMed Web of Science ®Google Scholar
• LOW NC, DU FORT GG, CERVANTES P: Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache (2003) 43:940–949.
   PubMed Web of Science ®Google Scholar
• STEVENS JA, OLSON S: Reducing falls and resulting hip fractures among older women. MMWR Recomm. Rep. (2000) 49:3–12.
   PubMedGoogle Scholar
• YONKERS KA, WISNER KL, STOWE Z et al: Management of bipolar disorder during pregnancy and the postpartum period. Am. J. Psychiatry (2004) 161:608–620.
   PubMed Web of Science ®Google Scholar
• CUNNINGTON M, TENNIS P: Lamotrigine and the risk of malformations in pregnancy. Neurology (2005) 64:955–960.
   PubMed Web of Science ®Google Scholar
• AMERICAN ACADEMY OF PEDIATRICS: Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Committee on Drugs. Pediatrics (2000) 105:880–887.
   PubMed Web of Science ®Google Scholar
• •A comprehensive state-of-knowledge review.
   Google Scholar
• GUILLE C, SACHS GS, GHAEMI SN: A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. I Clin. Psychiatry (2000) 61:638–642.
   PubMed Web of Science ®Google Scholar
• HUMMEL B, DITTMANN S, FORSTHOFF A et al: Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders: a case series. Neuropsychobiology (2002) 45\(Suppl. 1):37–42.
   Google Scholar
• ZARATE CA, TOHEN M, BANOV MD et al.: Is clozapine a mood stabilizer? Clin. Psychiatry (1995) 56:108–112.
   Google Scholar
• PURI BK, TAYLOR DG, ALCOCK ME: Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder. BE J. Clin. Pract. (1995) 49:333–334.
   PubMedGoogle Scholar
• GUPTA N, GROVER S: Safety of clozapine in 2 successive pregnancies. Can. J. Psychiatry (2004) 49:863.
   PubMed Web of Science ®Google Scholar
• TOHEN M, CHENGAPPA K, SUPPES T: Efficacy of olanzapine in combination with valproate or lithium for relapse prevention of bipolar disorder: an 18-month study. (2002).
   Google Scholar
• KINON BJ, BASSON BR, GILMORE JA et al.: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ./. Clin. Psychiatry (2001) 62:92–100.
   PubMed Web of Science ®Google Scholar
• TOHEN M, CHENGAPPA KN, SUPPES T et al: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry (2002) 59:62–69.
   PubMed Web of Science ®Google Scholar